Showing posts with label compulsory licensing. Show all posts
Showing posts with label compulsory licensing. Show all posts

Monday, March 26, 2012

Compulsory Licensing of Kaletra

Abbott's patent for Kaletra (ritonavir/lopinavir) has been annulled by a Brazilian federal Judge Daniela Pereira on constitutional grounds, meaning that the Brazilian government will now be able to purchase and dispense generic versions of the drug for its HIV-infected population. The nullification arises from anger at the cost of Kaletra, expressed by international advocacy groups last year in a call for compulsory licensing in several countries, including the US. For details I recommend Ed Silverman's post, Activists Challenge Abbott Over Its AIDS Drug.

The importance of Kaletra for HIV-treatment lies in the fact that a small percent of infected individuals do not respond to the first anti-retroviral with which they are treated, e.g., efavirenz. The ritonavir/lopinavir combination has literally proven lifesaving to these people. Another approach to assuring access to essential medications is that of Indian patent law, under which Abbott's patent application for Kaletra was denied because it sets a higher standard for what constitutes a new invention. This has the same result as the ruling in Brazil - the government has the opportunity to purchase significantly less expensive generic versions. As of the publication of the PLoS article, Trends in Compulsory Licensing of Pharmaceuticals Since the Doha Declaration: A Database Analysis, seventeen countries have taken the compulsory license route to providing health care access.


As the table indicates, Thailand granted several compulsory licenses early on after international negotiations led to the TRIPS agreement and the DOHA declaration. In Abbott's case, retaliation took the form of refusal to sell any of its drugs in Thailand and the withdrawal of applications for Thai patents. International public pressure caused the company to relent in one instance. A later, pediatric version of Kaletra was eventually sold in Thailand

Tuesday, February 21, 2012

Indian Compulsory Licensing Case May Reveal Research Costs

During the Superbowl, Amy O'Connor published a post on the Eli Lilly official company blog which has stimulated discussion of the research and development costs of a new drug. Her dollar amount was $1.3 billion, based on the methodology of the Tufts Center for Drug Development. In response Matthew Herper of Forbes published an estimate ranging from $3.7-11.8 billion. Merrill Goozner critiques the methodology that produced both these estimates in a blog post on GoozNews. At the other extreme of the range of estimates is the $43 million estimate from Light and Warburton in BioSocieties, rebutted by Derek Lowe in this post and a follow-up post on his blog, In the Pipeline.

Herper's estimated range has the advantage of being based on public information, but his approach is far too simplistic. Since Light and Warburton's article is behind a paywall, Timothy Noah's article in Slate is worth reading as long as you take account of Derek Lowe's criticisms. These high and low estimates revolve around the work done on the subject at Tufts. Their research is funded by various drug companies with the proviso that the dollar amounts of the costs they submit to the researchers remain confidential. Besides the required public information such as used in the Forbes' article, all drug companies are extremely protective of this information

So we arrive at an interesting situation which is developing in India. In my previous post, Compulsory Licensing of Proprietary Drugs, I referred to the public record of Natco's application for compulsory licensing of Bayer's proprietary drug Nexavar (sorafenib). LiveMint gives some history and the recent developments, which include the scheduled disclosure by Bayer of the research and development costs on which they base their price for the drug. Ed Silverman has an excellent post on what is required of drug companies who import brand name drugs to India. He links to articles in the Indian press that are also very worth reading. Compulsory licensing in India and elsewhere is based on the World Trade Organization's Declaration in the TRIPS [Trade-Related Aspects of Intellectual Property] Agreement and Public Health, commonly known as the Doha Declaration since it arose at the 4th Ministerial Conference in Doha, India. The Public Library of Science has published more background in a research article, Trends in Compulsory Licensing of Pharmaceuticals Since the Doha Declaration: A Database Analysis. Table 1 below is a summary from this article.